Categories
Breast Cancer

Key clinical trials investigating immunotherapy in HER2+ and HR+ breast cancer [Video]

Giuseppe Curigliano, MD, PhD, University of Milan and European Institute of Oncology, Milan, Italy, provides the rational for exploring the role of immunotherapy in HER-positive and hormone receptor (HR)-positive breast cancer and outlines key clinical trials. The Phase Ib/II trial PANACEA (NCT02129556) investigated the combination of trastuzumab and pembrolizumab in patients with HER2-positive metastatic breast cancer who had been heavily pretreated, demonstrating significant rates of progression-free survival (PFS). Phase III KATE3 (NCT04740918) explored the combination of trastuzumab emtansine plus atezolizumab in HER2-positive and PDL1-positive locally advanced or metastatic breast cancer, also showing significant PFS rates compared to the active comparator. The Phase III trial Astefania (NCT04873362) examined trastuzumab emtansine in combination with atezolizumab in patients with invasive breast cancer who are HER2- and PDL-1- positive. Prof. Curigliano additionally describes clinical trials investigating HR-positive breast cancer. Preliminary signs of activity were observed in the Phase II GELATO (NCT03147040) trial evaluating the combination of carboplatin plus atezolizumab specifically in patients with metastatic invasive lobular breast cancer. Further, a trial was reported evaluating treatment for patients with HR-positive, HER2-negative breast cancer with AC chemotherapy for three cycles followed by immune and endocrine therapy in the neoadjuvant setting. This trial was designed in regards to PAM50 molecular subtypes and it was noted that only patients with the basal-like subtype achieved pathologic complete response (pCR). Lastly, HER2 vaccines are discussed for patients with both HER2-positive and HER2-low breast cancer. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.

Categories
Breast Cancer

Key clinical trials in breast cancer presented at SABCS 2021 [Video]

Diogo Martins-Branco, MD, MSc, Institut Jules Bordet and Université Libre de Bruxelles (ULB), Brussels, Belgium, highlights the current key clinical trials in breast cancer at the San Antonio Breast Cancer Symposium 2021. Trials mentioned include the Phase II NIMBUS (NCT03789110) trial, which demonstrated activity of immune checkpoint inhibitors in patients with breast cancer with high tumor burden. The Phase III SOPHIA (NCT02492711) trial was shown to reinforce the significance of sequencing in metastatic breast cancer, advocating the use of technology to improve personalized treatment for patients with metastatic breast cancer. Dr. Martins-Branco reveals a novel finding was discovered in the Phase III EMERALD (NCT03778931) trial, showing prospective evidence for elacestrant as a superior alternative to the standard of care. Lastly, a trial is described in which the the TROP2-directed antibody-drug conjugate (ADC), datopotamab deruxtecan, demonstrated activity in triple negative breast cancer (TNBC), results that may play a significant role in the future for patients with TNBC. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.

Categories
Breast Cancer

Ovarian function suppression in premenopausal women with breast cancer [Video]

Meredith M. Regan, ScD, Harvard Medical School, Boston, MA, discusses the unknown benefit of chemotherapy in premenopausal woman currently under investigation in SOFT (NCT00066690) and TEXT (NCT00066703). Dr. Regan highlights the possible requirement for younger premenopausal woman to undergo ovarian function suppression (OFS) in addition to chemotherapy due to greater risk of recurrence in comparison to woman closer to menopause. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.

Categories
Breast Cancer

DEBBRAH: T-DXd in HER2+ or HER2-low advanced breast cancer with CNS involvement [Video]

Marta Vaz Batista, MD, Hospital Professor Doutor Fernando Fonseca, Amadora, Portugal, discusses the DEBBRAH trial (NCT04420598), a Phase II study evaluating trastuzumab deruxtecan (T-DXd) in patients with HER2-positive or HER2-low expressing advanced breast cancer and central nervous system (CNS) involvement. T-DXd demonstrated preliminary efficacy with manageable toxicity in pretreated patients with HER2+ advanced breast cancer with stable and progressing brain metastases after local treatment. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.

Categories
Breast Cancer

Real-world use of OncotypeDx testing in the management of breast cancer in the North East [Video]

Wendy Taylor, MBBS, and Abigail Gault, MBBS, MRCP, PGCert, Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK, provide an overview of the real-world use of OncotypeDx testing in the management of breast cancer in North East England. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.

Categories
Breast Cancer

RV-471: novel PROTAC® estrogen receptor degrader, in ER+ breast cancer [Video]

Erika Hamilton, MD, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN, discusses the safety results of the first-in-human study of ARV-471, a novel PROTAC® estrogen receptor degrader. ARV-471 was found to be well tolerated with no dose-limiting toxicities. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.

Categories
Breast Cancer

BioltaLEE: ctDNA dynamics in HR+/HER2- advanced breast cancer [Video]

Giampaolo Bianchini, MD, IRCCS San Raffaele Hospital, Milan, Italy, provides an overview of the circulating tumor DNA (ctDNA) dynamics in patients with HR+/HER2 advanced breast cancer who were enrolled in the BioltaLEE study This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.

Categories
Breast Cancer

EMERALD: elacestrant vs physicians choice in ER+/HER2- breast cancer [Video]

Erika Hamilton, MD, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN, discusses the results of the EMERALD study (NCT03778931), a randomized, open-label, Phase III trial evaluating the efficacy and safety of elacestrant, an oral selective estrogen receptor degrader (SERD), versus investigators choice of endocrine therapy for patients with ER+/HER2- advanced breast cancer following CDK46 inhibitor therapy. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.

Categories
Breast Cancer

Efficacy of TKIs in the treatment of HER2+ breast cancer with or without brain mets [Video]

Diogo Martins-Branco, MD, MSc, Institut Jules Bordet and Université Libre de Bruxelles (ULB), Brussels, Belgium, reports on the findings of a systematic review which aimed to assess the clinical outcomes of HER2+ metastatic breast cancer patients with or without brain metastases treated with TKI-containing regimens vs. those treated with non-TKI-containing regimens. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.